Array Biopharma files new-drug applications, stock price climbs

BOULDER — Cancer-research firm Array Biopharma Inc. (Nasdaq: ARRY) filed new-drug applications with the U.S. Food and Drug Administration.

The drug applications are for the combined use of 45 milligrams of binimetinib twice a day with 450 milligrams of encroafenib once a day for the treatment of patients with advanced or metastatic melanoma.

Array filed the applications after positive results from its phase three Columbus study. That study found that patients who use that combination of drugs have a survival rate without progression of the cancer that is longer than other drugs in use.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

Array’s stock price was $8.85 per share at the time of publication, a 15-cent increase from when the market closed on July 3, prior to the news of the drug applications.